Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma

Sundar Jagannath, MD
Published: Thursday, Jun 08, 2017



Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

There is a clinical trial ongoing with bb2121, which is a CAR T-cell therapy against a B-cell maturation antigen (BCMA). This is an ongoing phase I dose-escalation study, states Jagannath. The results demonstrate the first 11 patients could be escalated further.

Overall, this has been well tolerated. Cytokine release syndrome was experienced but has only been shown to be of grade 1/2, states Jagannath.
 


Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

There is a clinical trial ongoing with bb2121, which is a CAR T-cell therapy against a B-cell maturation antigen (BCMA). This is an ongoing phase I dose-escalation study, states Jagannath. The results demonstrate the first 11 patients could be escalated further.

Overall, this has been well tolerated. Cytokine release syndrome was experienced but has only been shown to be of grade 1/2, states Jagannath.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x